ArticleCost effectiveness and resource allocation : C/E2026
Inpatient medical costs and their composition among patients with stomach cancer who underwent surgery by tumor location: a hospital-based retrospective study in China.
Article in Cost effectiveness and resource allocation : C/E, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundStomach cancer (SC), the third leading cause of cancer-related death in China, poses a considerable challenge to the Chinese healthcare system. Evidence on inpatient medical costs and cost composition among patients with SC who underwent surgery in China remains limited. Using hospitalization billing data from Ningbo, China, this study estimates the total medical costs and cost composition of SC to gain insights into the economic burden due to SC in China.
methodsA hospital-based retrospective observational study was conducted using data from a tertiary hospital in Ningbo, China. SC-related medical expenditure and the sociodemographic and clinicopathologic characteristics of inpatients were obtained from the hospital billing system and inpatient medical records. Patients aged ≥ 18 years, with a primarily diagnosis of SC who underwent surgery between 2020 and 2023 were included in the study. The proportional breakdown of SC medical expenditure was analyzed by separating the expenditure into five major categories: materials, medications, surgery, examinations, and hospital services. All expenditure data were converted to 2020 Chinese Yuan.
resultsA total of 1,102 inpatients were included, where 69.51% were male, 69.06% were at stages I and II, and 58.89% had tumors in the lower part of the stomach. Inpatient medical costs were generally higher among older patients and patients with more advanced tumor stage. Materials, medications, and examinations were the major cost drivers of SC medical costs, jointly accounting for 73-74% of total costs across tumor sites.
conclusionsMedical costs among SC inpatients were substantial and varied across patients' sociodemographic and clinicopathological characteristics, particularly by age, tumor stage, and tumor site. These findings provide contemporary cost estimates that may inform hospital budgeting, procurement of medical materials and medications, and the refinement of reimbursement arrangements for SC hospitalization. They may also provide insights for future economic evaluations of SC prevention and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.